Latest Period
Q1 2026
Security Snapshot
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) Institutional Ownership
CUSIP: 92539P101
13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$11.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- VERV
- Shares outstanding
- 89,600,000
- Price per share
- $11.13
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 0
- Total reported value
- $0
- Share change
- -24,000
- Value change
- -$344,000
- Number of holders
- 0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 92539P101.
- 0 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 0 between Q4 2025 and Q1 2026.
- Reported value moved from $344,000 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 0 institutions filings for Q1 2026.
Security key
92539P101
Latest holder period
Q1 2026
13F holders
0
13D/G owners
4
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92539P101:
Significant Owners of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Pentwater Capital Management LP | 7.5% | $74,793,600 | 6,720,000 | Pentwater Capital Management LP | 30 Jun 2025 | |||
| BlackRock, Inc. | 7% | $33,730,520 | 6,177,751 | BlackRock, Inc. | 31 Mar 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 4.9% | +6% | $23,626,659 | +$2,228,204 | 4,327,227 | +10% | Millennium Management LLC | 22 Apr 2025 |
| STATE STREET CORP | 3.8% | $17,667,179 | 3,235,747 | STATE STREET CORPORATION | 31 Dec 2024 |
As of 31 Mar 2026, 0 institutional investors reported holding 0 shares of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV). This represents 0% of the company’s total 89,600,000 outstanding shares.
Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 0 | $0 | -$344,000 | $11.13 | 0 |
| 2025 Q4 | 24,000 | $344,000 | -$1,032,904 | $14.33 | 1 |
| 2025 Q3 | 115,958 | $1,373,904 | -$811,683,532 | $11.23 | 6 |
| 2025 Q2 | 72,945,086 | $819,295,389 | +$44,434,673 | $11.23 | 171 |
| 2025 Q1 | 80,771,198 | $369,085,158 | +$7,858,760 | $4.57 | 189 |
| 2024 Q4 | 78,639,409 | $443,556,247 | +$18,374,947 | $5.64 | 162 |
| 2024 Q3 | 75,254,197 | $364,246,240 | -$6,877,085 | $4.84 | 169 |
| 2024 Q2 | 76,097,271 | $371,356,824 | -$40,940,545 | $4.88 | 161 |
| 2024 Q1 | 81,620,346 | $1,084,037,472 | +$94,948,209 | $13.28 | 160 |
| 2023 Q4 | 74,728,462 | $1,041,701,866 | +$151,177,198 | $13.94 | 153 |
| 2023 Q3 | 63,876,196 | $847,014,395 | +$20,551,038 | $13.26 | 129 |
| 2023 Q2 | 61,868,280 | $1,159,985,777 | -$19,845,731 | $18.75 | 117 |
| 2023 Q1 | 63,279,802 | $911,809,584 | +$3,329,291 | $14.42 | 122 |
| 2022 Q4 | 62,650,868 | $1,212,293,655 | +$9,165,340 | $19.35 | 119 |
| 2022 Q3 | 60,715,323 | $2,083,329,620 | +$500,673,254 | $34.35 | 120 |
| 2022 Q2 | 45,570,006 | $695,801,719 | -$28,487,829 | $15.28 | 95 |
| 2022 Q1 | 46,647,422 | $1,064,194,664 | +$20,310,755 | $22.82 | 91 |
| 2021 Q4 | 45,147,057 | $1,662,481,200 | +$125,426,175 | $36.87 | 89 |
| 2021 Q3 | 38,717,676 | $1,813,712,011 | +$21,671,136 | $47.00 | 72 |
| 2021 Q2 | 37,677,821 | $2,254,528,000 | +$2,254,527,999 | $60.25 | 69 |